On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing. What happened According to a recent SEC filing, Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during the fourth quarter of 2025. The estimated value of the transaction is $81.38 million, calculated using the period's average closing price. The post-trade stake stood at 1,126,488 ...

Group 1 - Praxis Precision Medicines Inc. (NASDAQ:PRAX) is recognized as one of the 13 stocks with significant upside potential, with Wells Fargo initiating coverage with an Equal Weight rating and a price target of $282, while noting a 50% probability of success for its investigational drug ulixacaltamide [1][3] - The company anticipates potential peak revenue of up to $20 billion over the next 24 months from four drugs, including $10 billion from ulixacaltamide, $5 billion from relutrigine, $4 billion from vormatrigine for epilepsy, and around $1 billion from elsunersen [2] - Praxis is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance [3]

Core Insights - Praxis Precision Medicines (NASDAQ:PRAX) is identified as one of the 17 biotechnology stocks with significant upside potential, with analysts projecting over 140% upside [1] - Guggenheim analyst Yatin Suneja raised the price target for PRAX from $760 to $800, maintaining a Buy rating based on the market adoption potential of ulixacaltamide in essential tremor, which supports a market opportunity exceeding $15 billion [2] - H.C. Wainwright analyst Douglas Tsao also raised the price target for PRAX from $340 to $1,245, indicating a revised upside potential of 274% [3] Product and Market Potential - Ulixacaltamide is considered transformative for Praxis, with peak sales projections ranging from $5 billion to $10 billion, while relutrigine is expected to drive significant value with peak sales reaching $6.8 billion [4] - The company focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, including epilepsy, movement disorders, and depression [5]

Core Viewpoint - Praxis Precision Medicines Inc. is identified as a high-risk, high-reward growth stock, with Guggenheim raising its target price to $800, reflecting a 5.3% increase from the previous target of $760, and reiterating a Buy recommendation based on reassessed estimates for its drug Ulixacaltamide [1][4]. Group 1: Company Overview - Praxis Precision Medicines Inc. is a clinical-stage biopharma company focused on developing therapies for central nervous system disorders and genetic epilepsies, founded in September 2015 and based in Boston, Massachusetts [4]. Group 2: Drug Development and Market Potential - Ulixacaltamide, an orally administered drug for essential tremors, is projected to achieve peak sales between $5 billion and $10 billion within a $15+ billion market for essential tremors [1]. - The drug received "Breakthrough Therapy Designation" from the FDA in December 2025, which will expedite its review process and go-to-market timeline [2]. - Praxis plans to submit a New Drug Application (NDA) for Ulixacaltamide by February 2026, following positive interactions with the FDA [2].

Core Viewpoint - The article summarizes key analyst rating adjustments that are closely watched by Wall Street and can influence market trends, highlighting significant upgrades, downgrades, and new coverage ratings for various companies [1][5]. Upgraded Ratings - Aritet Investment upgraded Shopify (SHOP) from Neutral to Buy, raising the target price from $166 to $175, citing attractive valuation after recent weakness [6]. - William Blair upgraded Palantir (PLTR) from Market Perform to Outperform ahead of its earnings report, emphasizing valuation advantages as the core reason for the upgrade [6]. - BTIG raised McDonald's (MCD) rating from Neutral to Buy with a target price of $360, noting that research on franchisees indicates effective promotional strategies are driving customer traffic growth [6]. - JPMorgan upgraded Autodesk (ADSK) from Neutral to Overweight, maintaining a target price of $319, due to differentiated fundamentals in the vertical software as a service sector [6]. - JPMorgan raised Church & Dwight (CHD) from Underweight to Neutral, increasing the target price from $92 to $100, believing that business adjustments will lead to better sales growth [6]. Downgraded Ratings - JPMorgan downgraded Best Buy (BBY) from Overweight to Neutral, significantly lowering the target price from $99 to $76, anticipating an "unfavorable" earnings report for Q4 [6]. - Leith Wheeler downgraded BioNTech (BNTX) from Outperform to Market Perform, slightly raising the target price from $112 to $113, while expressing long-term optimism about the company's differentiated R&D potential [6]. - Canadian Imperial Bank downgraded Fortinet (FTNT) from Outperform to Sector Perform, maintaining a target price of $85, expressing caution about the stock's performance in 2026 [6]. - HSBC downgraded Chevron (CVX) from Buy to Hold, raising the target price from $169 to $180, citing valuation factors as the main reason for the downgrade [6]. - Morgan Stanley downgraded Humana (HUM) from Equal Weight to Underweight, significantly lowering the target price from $262 to $174, citing risks related to bidding strategies and policies affecting profit margin recovery [6]. New Coverage Ratings - Jefferies initiated coverage on Micron Technology (MU) with a Buy rating and a target price of $500, believing that the company's fourth-generation high-bandwidth memory (HBM4) will capture market share post Q2 [6]. - Morgan Stanley initiated coverage on Circle Network (CRCL) with an Equal Weight rating and a target price of $66, indicating that higher valuations are unlikely until stablecoin technology becomes more widely adopted [6]. - Citizens Bank initiated coverage on Stewart Information (STC) with an Outperform rating and a target price of $80, citing significant attractiveness at current valuation levels [6]. - Wells Fargo initiated coverage on Praxis Precision Medicines (PRAX) with an Equal Weight rating and a target price of $282, noting uncertainty regarding the approval prospects of the drug ulixacaltamide [6]. - Craig-Hallum initiated coverage on Simon Group (THR) with a Buy rating and a target price of $60, highlighting the company's improved business conditions and diversification benefiting from data center cooling technology trends [6].

Core Insights - Praxis Precision Medicines, Inc. (NASDAQ:PRAX) has shown remarkable performance with over 420% returns in the last three months, making it one of the top stocks to consider for investment [1] Group 1: Stock Performance and Analyst Ratings - Wedbush analyst Laura Chico raised the price target for PRAX from $83 to $95, attributing this increase to the company's recent public offering, which generated approximately $621 million in net proceeds [2] - Despite the price target increase, it indicates a significant downside of 66% from the stock's closing price of $280.86, and Wedbush maintains an Underperform rating for the shares [3] - Overall, Wall Street remains optimistic with a consensus Strong Buy rating and a one-year average price target of $456.71, suggesting an upside potential of 65.63% as of January 12 [3] Group 2: Corporate Outlook and Developments - The biopharmaceutical company has provided a corporate outlook for 2026, indicating multiple readouts scheduled in the next 12-24 months [4] - Praxis plans to submit two New Drug Applications (NDA) to the FDA in February for Ulixacaltamide targeting essential tumors and Relutrigine for SCN2A- and SCN8A-DEE [4] - The company focuses on developing therapies for central nervous system disorders using genetic insights [5]

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday.Shares of Bright Minds Biosciences Inc (NASDAQ:DRUG) fell sharply in pre-market trading after the company announced the launch of  a $100 million public offering.Bright Minds Biosciences shares dipped 2.3% to $91.03 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Cohen & Company Inc (NYSE:COHN) shares dipped 15.1% to $27.50 in pre-market trading after gaining 12% on Tuesday.G ...

Company Performance - Ultragenyx Pharmaceutical Inc. shares fell 42% to $19.84 following the announcement of Phase 3 study results for setrusumab (UX143) in Osteogenesis Imperfecta (OI) [1] - Mereo BioPharma Group plc shares dropped 90% to $0.23 after its Phase 3 studies for setrusumab did not achieve statistical significance against primary endpoints [5] Market Movements - Republic Power Group Ltd surged 163% to $0.69 [5] - Brand Engagement Network Inc jumped 84.3% to $2.21 after entering a Vendor Services Project Agreement [5] - DigitalBridge Group Inc rose 9.9% to $15.30 following the announcement of its acquisition by SoftBank Group for approximately $4.0 billion [5] Precious Metals Sector - Hycroft Mining Holding Corporation was down 14% to $21.61 as precious metal stocks traded lower due to a retreat in commodity prices [6] - Silver prices pulled back after reaching an all-time high, impacting related stocks [6]

Group 1 - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 100 points on Monday [1] - DigitalBridge Group Inc announced its acquisition by SoftBank Group for an enterprise value of approximately $4.0 billion, resulting in a 9.9% increase in its shares to $15.30 [1] Group 2 - Eightco Holdings Inc shares surged 29.1% to $2.15 following the announcement of a share buyback program for up to $125 million [2] - Palisade Bio Inc saw an 18.6% increase to $2.55 after Piper Sandler initiated coverage with an Overweight rating and a price target of $25 [2] - Regencell Bioscience Holdings Ltd gained 16.3% to $24.60 [2] - Praxis Precision Medicines Inc surged 13% to $304.00 after receiving Breakthrough Therapy Designation from the FDA for ulixacaltamide [2] - Zura Bio Ltd increased by 13% to $5.26 [2] - Precigen Inc rose 8.6% to $4.52 [2] - Autolus Therapeutics PLC jumped 7.8% to $1.80, with Needham analyst raising the price target from $10 to $11 [2] - LightPath Technologies Inc gained 6.6% to $9.62 [2] - NGL Energy Partners LP surged 6.3% to $9.98 [2] - Six Flags Entertainment Corp increased by 5% to $15.64 [2]

Core Insights - Praxis Precision Medicines Inc. is recognized as a promising biotech stock by Wall Street analysts, particularly due to its advancements in drug development for essential tremor and epilepsy [1][4] Group 1: Drug Development Progress - The company successfully completed a pre-New Drug Application meeting with the US FDA for Ulixacaltamide, an oral drug aimed at treating essential tremor, with plans to submit a New Drug Application early next year [1] - Positive results were confirmed from the EMBOLD study, which evaluated riluzole for patients with SCN2A- and SCN8A-related developmental and epileptic encephalopathies, showing a 53% placebo-adjusted reduction in seizures without serious adverse events [2] - Updated Phase 2 RADIANT trial data indicated that the candidate vormatrigine achieved nearly 100% median seizure reduction in focal onset seizures and about 80% in generalized epilepsy [3] Group 2: Analyst Ratings and Price Target - Analysts at TD Cowen reiterated a Buy rating on Praxis and raised the price target from $251 to $353, reflecting confidence in the company's epilepsy pipeline [3] - The interim EMBOLD results revealed that relutrigine provided a 53% placebo-adjusted reduction in seizures, contributing to the positive outlook from analysts [3]